Kenvue Inc.
KVUE
Updated: 22/09/2026, 23:45:04
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
No summaries found.
The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.
- Share price
- $17.86
- Market cap
- $34.29B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Kirk L. Perry
- Employees
- 21,890
- IPO date
- 04/05/2023
- Beta
- 0.426
- Last dividend
- $0.00
- Day range
- $17.84 – $17.99
- 52-week range
- $14.02 – $20.13
- 1-day performance
- 1.08%
- 1-year performance
- 27.39%
- Current drawdown (1Y)
- -11.28%
- CIK
- 0001944048
- CUSIP
- 49177J102
- ISIN
- US49177J1025
- Created
- 07/12/2025, 05:00:28
- Last update
- 22/09/2026, 23:45:04
Track Kenvue Inc. with an AI analyst
See which prediction-market events move KVUE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Best Consumer Dividend Stocks to Buy Now: HAS, KVUE, MOV
Zacks Investment Research • STOCK • 04/06/2026, 22:26:07
KVUE or LRLCY: Which Is the Better Value Stock Right Now?
Zacks Investment Research • STOCK • 25/05/2026, 14:40:19
Kimberly-Clark positioned for long-term value creation following Kenvue deal, says Bank of America
Proactive Investors • STOCK • 14/05/2026, 17:30:55
Kenvue (KVUE) Q1 Earnings and Revenues Beat Estimates
Zacks Investment Research • STOCK • 07/05/2026, 11:55:57
Kenvue to Announce First Quarter 2026 Results on May 7, 2026
Business Wire • STOCK • 23/04/2026, 18:32:00
Kimberly-Clark: This 5% Yielder Is A Buy Ahead Of The Kenvue Merger
Seeking Alpha • STOCK • 20/04/2026, 19:33:45
The Smartest Dividend Stocks to Buy With $2,000 Right Now
The Motley Fool • STOCK • 19/04/2026, 18:05:00
Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal
Reuters • STOCK • 15/04/2026, 11:52:19
Tylenol in pregnancy not linked with autism, Danish study finds
Reuters • STOCK • 13/04/2026, 16:09:47
Here's Why Kenvue (KVUE) Could be Great Choice for a Bottom Fisher
Zacks Investment Research • STOCK • 01/04/2026, 12:55:26
Kimberly-Clark's Dividend King Status Faces A Big Unknown
Seeking Alpha • STOCK • 13/03/2026, 16:25:48
KVUE vs. PG: Which Stock Is the Better Value Option?
Zacks Investment Research • STOCK • 04/03/2026, 13:41:14